Summit Trail Advisors’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $42.2K | Buy |
+20,000
| New | +$42.2K | ﹤0.01% | 1110 |
|
|
2024
Q4 | – | Sell |
-20,000
| Closed | -$55K | – | 524 |
|
|
2024
Q3 | $55K | Hold |
20,000
| – | – | ﹤0.01% | 710 |
|
|
2024
Q2 | $45.2K | Hold |
20,000
| – | – | ﹤0.01% | 609 |
|
|
2024
Q1 | $47.8K | Hold |
20,000
| – | – | ﹤0.01% | 594 |
|
|
2023
Q4 | $33.2K | Hold |
20,000
| – | – | ﹤0.01% | 551 |
|
|
2023
Q3 | $38.4K | Hold |
20,000
| – | – | ﹤0.01% | 539 |
|
|
2023
Q2 | $28.8K | Buy |
+20,000
| New | +$28.8K | ﹤0.01% | 538 |
|
|
2022
Q4 | – | Sell |
-23,855
| Closed | -$39K | – | 410 |
|
|
2022
Q3 | $39K | Hold |
23,855
| – | – | ﹤0.01% | 372 |
|
|
2022
Q2 | $31K | Hold |
23,855
| – | – | ﹤0.01% | 379 |
|
|
2022
Q1 | $38K | Buy |
+23,855
| New | +$38K | ﹤0.01% | 321 |
|